Affimed to Present at the 26th Annual Credit Suisse Healthcare Conference
November 02 2017 - 5:59AM
Heidelberg, Germany, November 2, 2017 - Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
focused on discovering and developing highly targeted cancer
immunotherapies, announced today that Dr. Adi Hoess, CEO, will
present at the 26th Annual Credit Suisse Healthcare Conference on
Wednesday, November 8, 2017 at 12:10 pm MT in Scottsdale,
Arizona.
A live webcast of the conference presentation
can be accessed through the "Events" section on the "Investors
& Media" page of the Affimed website at
http://www.affimed.com/events.php. A replay of the presentation
will be available from Affimed's website for 30 days following the
conference
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted
immunotherapies, seeking to cure patients by harnessing the power
of innate and adaptive immunity (NK and T cells). We are developing
single and combination therapies to treat cancers and other
life-threatening diseases. For more information, please visit
www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IRPhone: +49 6221
64793341
E-Mail: a.alexandru@affimed.com, IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024